Pubmed    Pubmed Central		uBio Home | uBioRSS
WebSearch Literature Molecular Images

uBio  Web  Results 71 - 80 of about 10147 Scientific:    Colisa lalia (Lal khailsha)  Synonyms:    Colisa lalia (Dwarf gourami)     Colisa lalius     Trichopodus lalius  Broader Terms:    Colisa     Lal     Perciformes (perch-like fishes)     Trichopodus      Latest Articles on Lal khailsha from uBioRSS Efficacy of a formalin-killed cell vaccine against infectious spleen and ki... - ScienceDirect Publication: Veterinary Microbiology Megalocytiviruses. - PubMed: species Colisa lalia Petr Pivoòka - BioLib External Resources: 71.  Biochemical analysis of leptospiral LPS explained the difference between pathogenic and non-pathogenic serogroups. Vanithamani S, Akino Mercy CS, Kanagavel M, Sumaiya K, Bothammal P, Saranya P, Prasad M, Ponmurugan K, Muralitharan G, Al-Dhabi NA, Verma A, Vijayachari P, Natarajaseenivasan K Microbial pathogenesis, 2021 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=0 72.  Utility of AI models in critical care: union of man and the machine. Lal A, Herasevich V, Gajic O Critical care (London, England), 2021 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=0 73.  Benefits of biologic therapy administered for asthma on co-existent chronic rhinosinusitis: A real-world study. Bajpai S, Marino MJ, Rank MA, Donaldson AM, O'Brien EK, Lal D International forum of allergy & rhinology Int Forum Allergy Rhinol Benefits of biologic therapy administered for asthma on co-existent chronic rhinosinusitis: A real-world study. 10.1002/alr.22774 Asthma and some chronic rhinosinusitis (CRS) subtypes are mediated by similar pathophysiologic mechanisms. The purpose of this study was to evaluate the effects of biologic therapy for asthma on co-existent CRS in the "real-world" setting. A review of electronic health records (2016-2019) at Mayo Clinic was conducted to identify asthma patients treated with biologics who had co-existent CRS. Matched-pair analyses compared pretherapy and posttherapy Lund-Mackay computed tomography (CT) scores and 22-item Sino-Nasal Outcome Test (SNOT-22) scores. Performance of endoscopic sinus surgery (ESS) after initiating biologics was studied. We identified 247 patients who received anti-asthma biologic therapy and had co-existent CRS. Of these, 181 patients (73.3%) had CRS with nasal polyposis (CRSwNP) and 66 (26.7%) had CRS without nasal polyposis (CRSsNP). The biologics utilized were omalizumab (51.0%), mepolizumab (46.6%), benralizumab (10.5%), reslizumab (1.6%), and dupilumab (2.4%). Anti-interleukin-5 (anti-IL-5) intervention was associated with significant improvement in CT scores (CRS overall, CRSwNP subgroup, CRSsNP subgroup) and SNOT-22 scores (CRS overall, CRSwNP subgroup). Patients on omalizumab had a decrease in CT scores, but not SNOT-22 scores. ESS was performed in 206 patients (84.1%); 55 (22.3%) underwent surgery post-biologic intervention (anti-IL-5: 16.5%; omalizumab 27.8% of patients). Anti-IL-5 agents were associated with improved CT and SNOT-22 scores in the overall CRS group and in CRSwNP subgroup; CRSsNP patients showed improved CT scores only. Omalizumab improved CT but not SNOT-22 scores. ESS was performed in 22% of patients after initiating biologics. These real-world results may influence future trial designs and clinical applications of biologics for CRS. ©2021 ARSAAOA, LLC. © 2021 ARS-AAOA, LLC. Bajpai Shilpika S University of Kansas School of Medicine, Kansas City, KS. Marino Michael J MJ Department of Otorhinolaryngology, Mayo Clinic, Phoenix, AZ. Rank Matthew A MA Department of Otorhinolaryngology, Mayo Clinic, Phoenix, AZ. Division of Allergy, Asthma, and Clinical Immunology, Mayo Clinic, Scottsdale, AZ. Donaldson Angela M AM Department of Otorhinolaryngology, Mayo Clinic, Jacksonville, FL. O'Brien Erin K EK https://orcid.org/0000-0002-4891-9548 Department of Otolaryngology-Head and Neck Surgery, Mayo Clinic, Rochester, MN. Lal Devyani D https://orcid.org/0000-0002-7593-2385 Department of Otorhinolaryngology, Mayo Clinic, Phoenix, AZ. eng Journal Article 2021 02 01 United States Int Forum Allergy Rhinol 101550261 2042-6976 IM asthma benralizumab biologic chronic rhinosinusitis dupilumab machine learning mepolizumab omalizumab reslizumab sinusitis therapy 2020 09 03 2021 01 08 2021 01 11 2021 2 2 6 21 2021 2 3 6 0 2021 2 3 6 0 aheadofprint 33527730 10.1002/alr.22774